1-20 of 43
Peter J. O’Dwyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT218: Phase II open label trial of Minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer

David Propper, Erkut Borazanci, Peter J. O'Dwyer, Daniel Von Hoff, Joseph Hartlebury, Corina E. Antal, Gerard I. Evan, HaiYong Han, Michael Downes, Ronald Evans, Joshua Rabinowitz, Emmanuel Petricoin, Ashok Saluja, Mohana Velagapudi, Hitendra Patel
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT218.
https://doi.org/10.1158/1538-7445.AM2024-CT218
Published: 05 April 2024
View article titled, Abstract CT218: Phase II open label trial of Minnelide™ in patients with chemotherapy refractory metastatic pancreatic cancer
Journal Articles

Abstract 1043: Liquid biopsy signature combining copy number instability and mutant KRAS detection is associated with survival for patients with metastatic pancreatic cancer

Samuele Cannas, Jacob E. Till, Kristine Kim, Michael J. LaRiviere, Charles M. Vollmer, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Kim A. Reiss Binder, Mark H. O'Hara, Douglas T. Ross, Kim McGregor, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Julia Beck, Erica L. Carpenter
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1043.
https://doi.org/10.1158/1538-7445.AM2023-1043
Published: 04 April 2023
View article titled, Abstract 1043: Liquid biopsy signature combining copy number instability and mutant <em>KRAS</em> detection is associated with survival for patients with metastatic pancreatic cancer
Journal Articles

Abstract A016: Phase 1 study of hypofractionated radiation in combination with tremelimumab and durvalumab in refractory metastatic pancreatic adenocarcinoma

Mark H. O'Hara, Adham S. Bear, Max M. Wattenberg, Ursina R. Teitelbaum, Kim A. Reiss, Thomas B. Karasic, Charles J. Schneider, Peter J. O'Dwyer, Edgar H. Ben-Josef, Andrzej P. Wojcieszynski, Amit H. Maity, Rosemarie H. Mick, Robert H. Vonderheide
Journal: Cancer Research
Cancer Res (2022) 82 (22_Supplement): A016.
https://doi.org/10.1158/1538-7445.PANCA22-A016
Published: 15 November 2022
View article titled, Abstract A016: Phase 1 study of hypofractionated radiation in combination with tremelimumab and durvalumab in refractory metastatic pancreatic adenocarcinoma
Journal Articles

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Vivek Subbiah, Fengmin Fengmin, Ragini Kudchadkar, Ryan J. Sullivan, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Xin Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Tilak K. Sundaresan, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT160.
https://doi.org/10.1158/1538-7445.AM2022-CT160
Published: 15 June 2022
View article titled, Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L
Journal Articles

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey Moscow, Robert J. Gray, Lisa M. McShane, Larry V. Rubenstein, David R. Patton, P Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT139.
https://doi.org/10.1158/1538-7445.AM2019-CT139
Published: 01 July 2019
View article titled, Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations
Journal Articles

Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations

Shivaani Kummar, Shuli Li, Kim Reiss, James M. Ford, Edith P. Mitchell, James A. Zwiebel, Naoko Takebe, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David Patton, Paul Mickey Williams, Stanley R. Hamilton, Adam Brufsky, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT138.
https://doi.org/10.1158/1538-7445.AM2019-CT138
Published: 01 July 2019
View article titled, Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <em>BRCA1</em> and <em>BRCA2</em> mutations
Journal Articles

Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors

Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zweibel, Fernanda I. Arnaldez, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry V. Rubenstein, David Patton, P Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Sameer S. Kasbari, Ravneet Thind, Barbara A. Conley, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-010.
https://doi.org/10.1158/1538-7445.AM2019-LB-010
Published: 01 July 2019
View article titled, Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for <em>CCND1, 2 or 3</em> amplified tumors
Journal Articles

Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2

Kim A. Reiss Binder, Rosemarie Mick, Mark O'Hara, Ursina Teitelbaum, Thomas Karasic, Charles Schneider, Peter J. O'Dwyer, Erica Carpenter, Austin Pantel, Mehran Makvandi, David Mankoff, Katherine Nathanson, Kara Maxwell, Stacy Cowden, Mary Jane Fuhrer, Janae Romeo, Gregory L. Beatty, Susan Domchek
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT234.
https://doi.org/10.1158/1538-7445.AM2019-CT234
Published: 01 July 2019
View article titled, Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in <em>BRCA1, BRCA2</em> or <em>PALB2</em>
Journal Articles

Abstract CT085: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial

Thomas B. Karasic, Mark H. O'Hara, Arturo Loaiza-Bonilla, Kim A. Reiss-Binder, Ursina R. Teitelbaum, Erkut Borazanci, Ana M. De Jesus-Acosta, Colleen Redlinger, Jessica A. Burrell, Daniel D. Von Hoff, Daniel A. Laheru, Ravi K. Amaravadi, Jeffrey A. Drebin, Peter J. O'Dwyer
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT085.
https://doi.org/10.1158/1538-7445.AM2018-CT085
Published: 01 July 2018
View article titled, Abstract CT085: Randomized phase II trial of hydroxychloroquine in combination with gemcitabine/nab-paclitaxel to inhibit autophagy in pancreatic cancer: A SU2C-funded trial
Journal Articles

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

Peter J. O’Dwyer, Sarina A. Piha-Paul, Christopher French, Sara Harward, Gerladine Ferron-Brady, Yuehui Wu, Olena Barbash, Anastasia Wyce, Meg Annan, Thierry Horner, Nigel J. Parr, Rab K. Prinjha, Christopher Carpenter, Geoffrey Shapiro, Arindam Dhar, Christine Hann
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT014.
https://doi.org/10.1158/1538-7445.AM2016-CT014
Published: 15 July 2016
View article titled, Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers
Journal Articles

Abstract 488: Inhibition of JNK signaling sensitizes hypoxic colon cancer cells to DNA-damaging agents

Irina A. Vasilevskaya, Muthu Selvakumaran, Lucia Cabal-Hierro, Peter J. O'Dwyer
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 488.
https://doi.org/10.1158/1538-7445.AM2014-488
Published: 01 October 2014
View article titled, Abstract 488: Inhibition of JNK signaling sensitizes hypoxic colon cancer cells to DNA-damaging agents
Journal Articles

Abstract 2274: RIP1-mediated sensitivity to SN38 induced by TNF in colon adenocarcinoma cell lines

Lucia Cabal-Hierro, Peter J. O'Dwyer
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2274.
https://doi.org/10.1158/1538-7445.AM2014-2274
Published: 01 October 2014
View article titled, Abstract 2274: RIP1-mediated sensitivity to SN38 induced by TNF in colon adenocarcinoma cell lines
Journal Articles

Abstract 2267: Inhibition of autophagy in hypoxic HT29 cells reverses hypoxia-induced resistance to oxaliplatin

Irina A. Vasilevskaya, Muthu Selvakumaran, David Roberts, Peter J. O'Dwyer
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2267.
https://doi.org/10.1158/1538-7445.AM2012-2267
Published: 15 April 2012
View article titled, Abstract 2267: Inhibition of autophagy in hypoxic HT29 cells reverses hypoxia-induced resistance to oxaliplatin
Journal Articles

Abstract 2872: Induction of autophagy in hypoxic HT29 cells requires functional JNK1

Irina A. Vasilevskaya, David Roberts, Peter J O'Dwyer
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2872.
https://doi.org/10.1158/1538-7445.AM2011-2872
Published: 15 April 2011
View article titled, Abstract 2872: Induction of autophagy in hypoxic HT29 cells requires functional JNK1
Journal Articles

Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors

Kenneth M. Algazy, Lynn M. Schuchter, Angela M. Demichele, Vaughn J. David, Drew A. Torigian, Claire Y. Chang, Maryann Redlinger, Lisa E. Davis, Peter J. O'Dwyer, Ravi K. Amaravadi
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4500.
https://doi.org/10.1158/1538-7445.AM2011-4500
Published: 15 April 2011
View article titled, Abstract 4500: Combined mTOR inhibition and autophagy inhibition: Phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors
Journal Articles

Abstract 2521: Combining chemotherapy with autophagy inhibition: Phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors

Leslie A. Fecher, Lynn M. Schuchter, Tracey Evans, Claire Y. Chang, Maryann Gallagher, Amy Kramer, Peter J. O'Dwyer, Ravi K. Amaravadi
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2521.
https://doi.org/10.1158/1538-7445.AM2011-2521
Published: 15 April 2011
View article titled, Abstract 2521: Combining chemotherapy with autophagy inhibition: Phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors
Journal Articles

Abstract 87: Differential effects of JNK1 and JNK2 on cell death in hypoxic colon cancer cell lines

Irina A. Vasilevskaya, Muthu Selvakumaran, David Roberts, Peter J. O'Dwyer
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 87.
https://doi.org/10.1158/1538-7445.AM10-87
Published: 15 April 2010
View article titled, Abstract 87: Differential effects of JNK1 and JNK2 on cell death in hypoxic colon cancer cell lines
Journal Articles

A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis

Pål Sætrom, Jacob Biesinger, Sierra M. Li, David Smith, Laurent F. Thomas, Karim Majzoub, Guillermo E. Rivas, Jessica Alluin, John J. Rossi, Theodore G. Krontiris, Jeffrey Weitzel, Mary B. Daly, Al B. Benson, John M. Kirkwood, Peter J. O'Dwyer, Rebecca Sutphen, James A. Stewart, David Johnson, Garrett P. Larson
Journal: Cancer Research
Cancer Res (2009) 69 (18): 7459–7465.
https://doi.org/10.1158/0008-5472.CAN-09-1201
Published: 14 September 2009
View article titled, A Risk Variant in an miR-125b Binding Site in <em>BMPR1B</em> Is Associated with Breast Cancer Pathogenesis
Open the PDF for A Risk Variant in an miR-125b Binding Site in <em>BMPR1B</em> Is Associated with Breast Cancer Pathogenesis in another window
Includes: Supplementary data
Journal Articles

Activation of c-Jun/AP-1 in hypoxic HT29 colon adenocarcinoma cells requires functional MKK7

Irina A. Vasilevskaya, Peter J. O’Dwyer
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 969.
Published: 15 April 2006
View article titled, Activation of c-Jun/AP-1 in hypoxic HT29 colon adenocarcinoma cells requires functional MKK7
Journal Articles

Differing mechanisms of synergistic interaction of the hsp90 inhibitor 17-AAG and TRAIL in resistant colon cancer cell lines

Irina A. Vasilevskaya, Peter J. O’Dwyer
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 780.
Published: 01 May 2005
View article titled, Differing mechanisms of synergistic interaction of the hsp90 inhibitor 17-AAG and TRAIL in resistant colon cancer cell lines